The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Open accessAbstract
Interleukin-15 (IL-15) promotes the survival of T lymphocytes and enhances the antitumour properties of chimeric antigen receptor (CAR) T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy1, 2, 3–4. Glypican-3 (GPC3) is expressed in a group of solid cancers5, 6, 7, 8, 9–10, and here we report the evaluation in humans of the effects of IL-15 co-expression on GPC3-expressing CAR T cells (hereafter GPC3 CAR T cells). Cohort 1 patients (NCT02905188 and NCT02932956) received GPC3 CAR T cells, which were safe but produced no objective antitumour responses and reached peak expansion at 2 weeks. Cohort 2 patients (NCT05103631 and NCT04377932) received GPC3 CAR T cells that co-expressed IL-15 (15.CAR), which mediated significantly increased cell expansion and induced a disease control rate of 66% and antitumour response rate of 33%. Infusion of 15.CAR T cells was associated with increased incidence of cytokine release syndrome, which was controlled with IL-1/IL-6 blockade or rapidly ameliorated by activation of the inducible caspase 9 safety switch. Compared with non-responders, tumour-infiltrating 15.CAR T cells from responders showed repression of SWI/SNF epigenetic regulators and upregulation of FOS and JUN family members, as well as of genes related to type I interferon signalling. Collectively, these results demonstrate that IL-15 increases the expansion, intratumoural survival and antitumour activity of GPC3 CAR T cells in patients. We evaluate the effects in humans of interleukin-15 co-expression on glypican-3 (GPC3) chimeric antigen receptor (CAR) T cells and demonstrate that IL-15 increases the expansion, intratumoural survival and antitumour activity of GPC3 (expressed in a group of solid cancers) CAR T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Fast, sensitive and accurate integration of single-cell data with Harmony
Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., & Raychaudhuri, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0619-0 · Cited by 10,488
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Self-citationc-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891 · cited 1×
“CAR T cells co-expressing JUN had increased antitumour activity in non-clinical models 41 , and our results demonstrate the importance of FOS and JUN subfamily members, because these genes were significantly upregulated in tumour-infiltrating 15.CAR T cells in responders.”
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., et al. (2022) · Nature · doi:10.1038/s41586-022-04489-4 · Cited by 823
Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905675116 · Cited by 808
Xu, Y., Zhang, M., Ramos, C. A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, C. J., Gee, A. P., Heslop, H. E., et al. (2014) · Blood · doi:10.1182/blood-2014-01-552174 · Cited by 744
Self-citationAn inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742
Self-citationConlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
scRepertoire: An R-based toolkit for single-cell immune receptor analysis
Borcherding, N., & Bormann, N. L. (2020) · F1000Research · doi:10.12688/f1000research.22139.1 · Cited by 603
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600 · cited 1×
“Specific transcriptomic and cell surface phenotypic characteristics of CAR T cell infusion products have been associated with differences in clinical outcomes 23,24 .”
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Self-citationGD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2210859 · Cited by 561
Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
Krishna, S., Lowery, F. J., Copeland, A. R., Bahadiroglu, E., Mukherjee, R., Jia, L., Anibal, J. T., Sachs, A., Adebola, S. O., Gurusamy, D., et al. (2020) · Science · doi:10.1126/science.abb9847 · Cited by 547
An NK-like CAR T cell transition in CAR T cell dysfunction
Good, C. R., Aznar, M. A., Kuramitsu, S., Samareh, P., Agarwal, S., Donahue, G., Ishiyama, K., Wellhausen, N., Rennels, A. K., Ma, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.016 · Cited by 396
Belk, J. A., Yao, W., Ly, N., Freitas, K. A., Chen, Y.-T., Shi, Q., Valencia, A. M., Shifrut, E., Kale, N., Yost, K. E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.001 · Cited by 382
Shi, D., Shi, Y., Kaseb, A. O., Qi, X., Zhang, Y., Chi, J., Lu, Q., Gao, H., Jiang, H., Wang, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3259 · Cited by 378
Fehniger, T. A., Suzuki, K., Ponnappan, A., VanDeusen, J. B., Cooper, M. A., Florea, S. M., Freud, A. G., Robinson, M. L., Durbin, J., & Caligiuri, M. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.219 · Cited by 373
Rossi, J., Paczkowski, P., Shen, Y.-W., Morse, K., Flynn, B., Kaiser, A., Ng, C., Gallatin, K., Cain, T., Fan, R., et al. (2018) · Blood · doi:10.1182/blood-2018-01-828343 · Cited by 330
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
Wang, C., Lin, G. H. Y., McPherson, A. J., & Watts, T. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00765.x · Cited by 298
Batra, S. A., Rathi, P., Guo, L., Courtney, A. N., Fleurence, J., Balzeau, J., Shaik, R. S., Nguyen, T. P., Wu, M.-F., Bulsara, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0293 · Cited by 268
Self-citationGlypican-3: A new target for cancer immunotherapy
Ho, M., & Kim, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.024 · Cited by 235
Mlecnik, B., Bindea, G., Angell, H. K., Sasso, M. S., Obenauf, A. C., Fredriksen, T., Lafontaine, L., Bilocq, A. M., Kirilovsky, A., Tosolini, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007240 · Cited by 223
CAR T‐cell therapy of solid tumors
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2016.128 · Cited by 220
Bosse, K. R., Raman, P., Zhu, Z., Lane, M., Martinez, D., Heitzeneder, S., Rathi, K. S., Kendsersky, N. M., Randall, M., Donovan, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.003 · Cited by 215
Self-citationChen, Y., Sun, C., Landoni, E., Metelitsa, L., Dotti, G., & Savoldo, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1811 · Cited by 204
Self-citationZhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., Ohishi, N., Ohtomo, T., & Philip, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2616 · Cited by 193
Glypican 3: A Novel Marker in Testicular Germ Cell Tumors
Zynger, D. L., Dimov, N. D., Luan, C., Tean Teh, B., & Yang, X. J. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213322.89670.48 · Cited by 185
Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1129483 · Cited by 178
Anti–Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Ishiguro, T., Sugimoto, M., Kinoshita, Y., Miyazaki, Y., Nakano, K., Tsunoda, H., Sugo, I., Ohizumi, I., Aburatani, H., Hamakubo, T., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1973 · Cited by 168
Lukhele, S., Abd-Rabbo, D., Guo, M., Shen, J., Elsaesser, H. J., Quevedo, R., Carew, M., Gadalla, R., Snell, L. M., Mahesh, L., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.020 · Cited by 144
IL15 and T-cell Stemness in T-cell–Based Cancer Immunotherapy
Pilipow, K., Roberto, A., Roederer, M., Waldmann, T. A., Mavilio, D., & Lugli, E. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1498 · Cited by 143
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
Haruyama, Y., & Kataoka, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.275 · Cited by 142
Li, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.-F., Liu, H., Dotti, G., Gottschalk, S. M., Metelitsa, L. S., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.025 · Cited by 114
Self-citationLayilin augments integrin activation to promote antitumor immunity
Mahuron, K. M., Moreau, J. M., Glasgow, J. E., Boda, D. P., Pauli, M. L., Gouirand, V., Panjabi, L., Grewal, R., Luber, J. M., Mathur, A. N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192080 · Cited by 62
Jung, I.-Y., Bartoszek, R. L., Rech, A. J., Collins, S. M., Ooi, S., Williams, E. F., Hopkins, C. R., Narayan, V., Haas, N. B., Frey, N. V., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1175 · Cited by 38
Glypican 3 overexpression in primary and metastatic Wilms tumors
Tretiakova, M., Zynger, D. L., Luan, C., Andeen, N. K., Finn, L. S., Kocherginsky, M., Teh, B. T., & Yang, X. J. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1669-4 · Cited by 34
Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties
Upadhye, A., Landeros, K. E. M., Ramírez-Suástegui, C., Schmiedel, B. J., Woo, E. B. C., Chee, S., Malicki, D. M., Coufal, N. G., Gonda, D. D., Levy, M. L., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00706-9 · Cited by 19
Gardner, R., Finney, O. C., Brakke, H., Rawlings-Rhea, S. D., Hicks, R. M., Doolittle, D., López, M. I. E., Orentas, R. J., Li, D., & Jensen, M. C. (2018) · Blood · doi:10.1182/blood-2018-99-117493 · Cited by 14
Cited by
Du, B., Qin, J., Lin, B., Zhang, J., Li, D., & Liu, M. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.019 · Cited by 254
Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy
Couzinet, A., Suzuki, T., & Nakatsura, T. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2416975 · Cited by 27
Metadata
- Authors
- Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., Masand, P., Maris, J. M., Martinez, D., Pogoriler, J., Varadarajan, N., Thakkar, S. G., Lyon, D., Lapteva, N., Zhuyong, M., Patel, K., Lopez-Terrada, D., Ramos, C. A., Lulla, P., Armaghany, T., Grilley, B. J., Gottschalk, S., Dotti, G., Metelitsa, L. S., Heslop, H. E., Brenner, M. K., Sumazin, P., & Heczey, A.
- Venue
- Nature
- Published
- 2024-11-27
- Volume
- 637
- Issue
- 8047
- Pages
- 940-946
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4404754574
- Cited by
- 289
- References
- 45
- FWCI
- 44.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.